(Q34512903)

2 August 2017

1 reference

title

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

2 August 2017

main subject

1 reference

1 reference

1 reference

John E Nestler

1

1 reference

2 August 2017

Dale Stovall

2

1 reference

2 August 2017

Nausheen Akhter

3

1 reference

2 August 2017

Maria J Iuorno

4

1 reference

2 August 2017

Daniela J Jakubowicz

5

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

2 August 2017

published in

Fertility and Sterility

1 reference

2 August 2017

volume

77

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

209-215

1 reference

Insulin resistance in nonobese patients with polycystic ovarian disease

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Clinical and laboratory predictors of clomiphene response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Menstrual Cyclicity After Metformin Therapy in Polycystic Ovary Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Hypersecretion of luteinising hormone, infertility, and miscarriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Recurrent early miscarriage and polycystic ovaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Subfertility and risk of spontaneous abortion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Influence of past reproductive performance on risk of spontaneous abortion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Obesity is a risk factor for early pregnancy loss after IVF or ICSI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

Metformin in management of pregnant insulin-independent diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

The management of non-insulin-dependent diabetes during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2902963-6

10.1016/S0015-0282(01)02963-6

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference